Shan Lin

Shan Lin

Auto-generated profile, based on publicly available information

Shan Lin

Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Cancer Cell
Verified
Journal Article
Closed access
SLShan Lin
Shan Lin
RLRoger T. Luo
Roger T. Luo
APAnetta Ptasinska
Anetta Ptasinska
JKJon Kerry
Jon Kerry
SASalam A. Assi
Salam A. Assi
MTMichael J. Thirman
Michael J. Thirman

26 April 2016 in EMBO Reports
Verified
Journal Article
Closed access
PDF file
NTNgoc‐Tung Tran
Ngoc‐Tung Tran
HSHairui Su
Hairui Su
AKAlireza Khodadadi‐Jamayran
Alireza Khodadadi‐Jamayran
SLShan Lin
Shan Lin
LZLi Zhang
Li Zhang
XZXinyang Zhao
Xinyang Zhao

16 September 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
SLShan Lin
Shan Lin
CLClément Larrue
Clément Larrue
NSNastassja K. Scheidegger
Nastassja K. Scheidegger
BSBo Kyung A. Seong
Bo Kyung A. Seong
NDNeekesh V. Dharia
Neekesh V. Dharia
KSKimberly Stegmaier
Kimberly Stegmaier
CRISPR–Cas9-based genetic screens have successfully identified cell type–dependent liabilities in cancer, including acute myeloid leukemia (AML), a devastating hematologic malignancy with poor overall survival. Because most of these screens have been performed in vitro using established cell lines, evaluating the physiologic relevance of these targets is critical. We have established a CRISPR screening approach using orthotopic xenograft models to validate and prioritize AML-enriched dependencies in vivo, including in CRISPR-competent AML patient-derived xenograft (PDX) models tractable for genome editing. Our integrated pipeline has revealed several targets with translational value, including SLC5A3 as a metabolic vulnerability for AML addicted to exogenous myo-inositol and MARCH5 as a critical guardian to prevent apoptosis in AML. MARCH5 repression enhanced the efficacy of BCL2 inhibitors such as venetoclax, further highlighting the clinical potential of targeting MARCH5 in AML. Our study provides a valuable strategy for discovery and prioritization of new candidate AML therapeutic targets. Significance: There is an unmet need to improve the clinical outcome of AML. We developed an integrated in vivo screening approach to prioritize and validate AML dependencies with high translational potential. We identified SLC5A3 as a metabolic vulnerability and MARCH5 as a critical apoptosis regulator in AML, both of which represent novel therapeutic opportunities. This article is highlighted in the In This Issue feature, p. 275

2 January 2020 in Blood
Verified
Journal Article
Open access
PDF file
YTYusuke Tarumoto
Yusuke Tarumoto
SLShan Lin
Shan Lin
JWJinhua Wang
Jinhua Wang
JMJoseph P. Milazzo
Joseph P. Milazzo
YXYali Xu
Yali Xu
CVChristopher R. Vakoc
Christopher R. Vakoc
Transcription factors are important drivers in acute myeloid leukemia (AML), but they are notoriously difficult to target. The authors demonstrate that inhibition of salt-inducible kinase (SIK3) inhibits AML cell proliferation in cells dependent on the transcription factor MEF2C, identifying a small molecule that can disrupt a leukemogenic transcription factor pathway.

9 October 2015 in Leukemia
Verified
Journal Article
Closed access
PDF file
SGS Goyama
S Goyama
JSJ Schibler
J Schibler
AGA Gasilina
A Gasilina
MSM Shrestha
M Shrestha
SLS Lin
S Lin
JMJ C Mulloy
J C Mulloy

11 April 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
JEJana M. Ellegast
Jana M. Ellegast
GAGabriela Alexe
Gabriela Alexe
AHAmanda Hamze
Amanda Hamze
SLShan Lin
Shan Lin
HUHannah J. Uckelmann
Hannah J. Uckelmann
KSKimberly Stegmaier
Kimberly Stegmaier
Leukemic blasts are immune cells gone awry. We hypothesized that dysregulation of inflammatory pathways contributes to the maintenance of their leukemic state and can be exploited as cell-intrinsic, self-directed immunotherapy. To this end, we applied genome-wide screens to discover genetic vulnerabilities in acute myeloid leukemia (AML) cells implicated in inflammatory pathways. We identified the immune modulator IRF2BP2 as a selective AML dependency. We validated AML cell dependency on IRF2BP2 with genetic and protein degradation approaches in vitro and genetically in vivo. Chromatin and global gene-expression studies demonstrated that IRF2BP2 represses IL1β/TNFα signaling via NFκB, and IRF2BP2 perturbation results in an acute inflammatory state leading to AML cell death. These findings elucidate a hitherto unexplored AML dependency, reveal cell-intrinsic inflammatory signaling as a mechanism priming leukemic blasts for regulated cell death, and establish IRF2BP2-mediated transcriptional repression as a mechanism for blast survival. Significance: This study exploits inflammatory programs inherent to AML blasts to identify genetic vulnerabilities in this disease. In doing so, we determined that AML cells are dependent on the transcriptional repressive activity of IRF2BP2 for their survival, revealing cell-intrinsic inflammation as a mechanism priming leukemic blasts for regulated cell death. See related commentary by Puissant and Medyouf, p. 1617. This article is highlighted in the In This Issue feature, p. 1599